BiotechTube

Tasocitinib + Tasocitinib + vehicle for Tasocitinib

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Keratoconjunctivitis Sicca

Conditions

Keratoconjunctivitis Sicca

Trial Timeline

Dec 1, 2010 → Oct 19, 2012

NCT ID
NCT01226680

About Tasocitinib + Tasocitinib + vehicle for Tasocitinib

Tasocitinib + Tasocitinib + vehicle for Tasocitinib is a phase 2 stage product being developed by Pfizer for Keratoconjunctivitis Sicca. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01226680. Target conditions include Keratoconjunctivitis Sicca.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01226680Phase 2Withdrawn

Competing Products

15 competing products in Keratoconjunctivitis Sicca

See all competitors
ProductCompanyStageHype Score
FK506Astellas PharmaPhase 3
77
FK506 + placeboAstellas PharmaPhase 3
77
OTX-101 0.09%Sun PharmaceuticalPhase 3
77
OTX-101 0.05% + OTX-101 0.09% + VehicleSun PharmaceuticalPhase 2/3
65
cyclosporine + vehicle of OTX-101Sun PharmaceuticalPhase 3
77
INS365 Ophthalmic SolutionMerckPhase 3
77
Pimecrolimus + VehicleNovartisPhase 2
52
Cyclosporine A + DexamethasoneNovartisApproved
85
RebamipideNovartisPhase 3
77
RebamipideNovartisPhase 3
77
DupilumabRegeneron PharmaceuticalsPhase 2
51
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + R348 Ophthalmic Solution, 1.0% + PlaceboRigel PharmaceuticalsPhase 1
25
R348 Ophthalmic Solution, 0.2% + R348 Ophthalmic Solution, 0.5% + PlaceboRigel PharmaceuticalsPhase 2
44
CF101Can Fite BiopharmaPhase 3
69
CF101 + PlaceboCan Fite BiopharmaPhase 2
44

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84